Dual AAV gene therapy achieves recovery of hearing and auditory processing in a DFNB16 mouse model

Abstract

Graphical Abstract DFNB16 is among the most prevalent forms of congenital deafness, caused by mutations in the Stereocilin gene. Although no treatment currently exists, gene therapy represents a promising curative approach. Here, we demonstrate that AAV-mediated gene delivery in a DFNB16 mouse model restored both peripheral hearing and central auditory processing.